Reimbursement As Important As Regulatory Risks In Investment Decisions – Venture Capitalist
This article was originally published in The Pink Sheet Daily
Executive Summary
Venture capitalists are considering whether payers will pay and what reimbursement codes are available as they assess whether to put their money in companies with new medical products, a St. Louis venture capitalist tells regulatory affairs specialists in Seattle Oct. 28.